Background/Aims: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor afatinib is used for the treatment of several malignancies. Afatinib is at least partially effective by triggering apoptosis of tumor cells. Platelets may similarly undergo apoptosis, which is characterized by caspase 3 activation, cell shrinkage and phosphatidylserine translocation. However, an effect of afatinib on platelets has never been reported. The present study explored whether treatment of platelets with afatinib modifies platelet activation and apoptosis in the absence and presence of platelet activators thrombin or collagen related peptide (CRP). Methods: Platelets isolated from wild-type mice were exposed for 30 minutes to afatinib (18 µg/ml) without or with subsequent treatment with thrombin (0.005 U/ml or 0.01 U/ml) or CRP (2 µg/ml or 5 µg/ml). Flow cytometry was employed to estimate Orai1 abundance at the platelet surface with specific antibodies, cytosolic Ca 2+ -activity ([Ca 2+ ] i ) from Fluo-3 fluorescence, platelet degranulation from P-selectin abundance, integrin activation from α IIb β 3 integrin abundance, caspase activity utilizing an Active Caspase-3 Staining kit, phosphatidylserine abundance from annexin-V-binding, platelet volume from forward scatter and aggregation utilizing staining with CD9-APC and CD9-PE. Results: In the absence of thrombin and CRP, the administration of afatinib (18 µg/ml) slightly, but significantly, increased [Ca 2+ ] i and annexin-V-binding, but did not significantly modify Orai1 abundance, P-selectin abundance, activated α IIb β 3 integrin, cell volume, caspase activity and aggregation. Exposure of platelets to 0.005 U/ml or 0.01 U/ml thrombin or 2 µg/ml or 5 µg/ ml CRP was followed by a significant increase of Orai1 abundance, increase of [Ca 2+ ] i , P-selectin abundance, α IIb β 3 integrin activity, annexin-V-binding, caspase activity, and aggregation, as well as a significant decrease of forward scatter, all effects significantly blunted (thrombin) or virtually abolished (CRP) by afatinib. Conclusions: Afatinib is a powerful inhibitor of platelet activation, platelet apoptosis and platelet aggregation.
Introduction
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor afatinib is used for the treatment of several malignancies [1, 2] including non-small cell lung cancer [3] [4] [5] [6] , metastatic lung carcinoma [7] , and metastatic squamous cell carcinoma [8, 9] . Afatinib is at least in part effective by triggering tumor cell apoptosis [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Similar to nucleated cells, blood platelets may undergo apoptosis, characterized by caspase activation, cell shrinkage, and cell membrane scrambling with phosphatidylserine translocation to the cell surface [24, 25] . Platelets participate in the orchestration of primary hemostasis following vascular injury and contribute to the pathophysiology of acute thrombotic occlusion [26, 27] . Deranged platelet function may thus result in arterial thrombosis, vascular inflammation and atherogenesis [27, 28] .
Platelets are activated by increase of cytosolic Ca 2+ concentration ([Ca 2+ ] i ) [29] secondary to Ca 2+ release from intracellular stores [30] and subsequent activation of Ca 2+ release-activated Ca 2+ channel Orai1 in the plasma membrane [29, [31] [32] [33] . To the best of our knowledge, nothing is known about an effect of afatinib on platelet function or survival. The present study thus explored whether afatinib influences activation and/ or apoptosis of blood platelets.
Materials and Methods

Mice
All animal experiments were conducted according to the German law for the welfare of animals and were approved by the authorities of the state of Baden-Württemberg. Experiments were performed with blood platelets isolated from wild type mice. The mice had free access to water and control chow (Ssniff, Soest, Germany). Mice have been studied in view of their low interindividual variability.
Preparation of mouse platelets
Platelets were obtained from 10-to 12-week-old mice of either sex. The mice were anesthetized and 800 µl blood was drawn from the retro-orbital plexus into tubes with 200 µl acid-citrate-dextrose buffer before the mice were sacrificed [34] . Platelet rich plasma (PRP) was obtained by centrifugation at 260 g for 5 minutes. Afterwards, PRP was centrifuged at 640 g for 5 minutes to pellet the platelets. Where necessary, apyrase (0.02 U/ml; Sigma-Aldrich) and prostaglandin I 2 (0.5 µM; Calbiochem) were added to the PRP to prevent activation of platelets during isolation [35] . After two washing steps, the pellet of washed platelets was resuspended in modified Tyrode-HEPES buffer (pH 7.4, supplemented with 1 mM CaCl 2 ). Where indicated, thrombin (Roche，Basel， Switzerland) or collagen related peptide (kindly provided by R. Farndale, University of Cambridge, Cambridge, UK) was added at the indicated concentrations [36] . 
Orai1 abundance at platelet surface
Cytosolic calcium
For the measurement of the cytosolic Ca 2+ concentration, the platelet preparation was washed once in Tyrode buffer (pH 7.4), stained with 3 µM Fluo-3AM (Biotinium, USA) in the same buffer and incubated at 37°C for 30 minutes. Following the indicated experimental treatment, relative fluorescence was measured utilizing a BD FACS Calibur (BD Biosciences, Heidelberg, Germany) [37] .
P-selectin and activated integrin abundance
Fluorophore-labeled antibodies were utilized for the detection of P-selectin expression (Wug.E9-FITC) [38] and the active form of α IIb β 3 integrin (JON/A-PE) [39] . Washed mouse platelets (1x10 6 ) were suspended in modified Tyrode buffer (pH 7.4) containing 1 mM CaCl 2 and antibodies (1:10 dilution) and subsequently subjected to the respective treatments and for the indicated time periods at room temperature (RT). The reaction was stopped by addition of PBS and the samples were immediately analyzed on a BD FACSCalibur.
Phosphatidylserine exposure and forward scatter
In order to estimate phosphatidylserine exposure, the platelet preparation was centrifuged at 660 g for 5 minutes followed by washing once with Tyrode buffer (pH 7.4) with 1 mM CaCl 2 , staining with 1:20 dilution of Annexin-V FITC (Mabtag, Germany) in Tyrode buffer (pH 7.4) with 2 mM CaCl 2 and incubation at 37 o C for 30 minutes. Annexin-V binding reflecting surface exposure of phosphatidylserine was evaluated by flow cytometry utilizing a BD FACSCalibur. In parallel, the forward scatter (FSC) of the platelets was determined by flow cytometry as a measure of platelet size [40] .
Caspase-3 activity Caspase 3 activity was determined utilizing a CaspGlow Fluorescein Active Caspase-3 Staining kit from BioVision (CA, USA) following incubation at 37 o C for 30 minutes. Fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 on a BD FACSCalibur (BD Biosciences, USA).
Platelet aggregation
Aggregation was determined utilizing flow cytometry as previously described [41] . To this end, platelets were labeled with CD9-APC and CD9-PE monoclonal antibodies (1:100 dilution, Abcam) for 15 minutes at room temperature. Following incubation, differently labeled samples were washed twice, mixed 1:1, and incubated in 18 µg/ml afatinib (R&D, Germany) for 30 min at 37 o C while shaking at 600 rpm for 10 minutes. The shaking prevented spontaneous aggregation. Pre-incubated platelets were activated with 0.005 U/ml thrombin or 2 µg/ml CRP at 37 o C while shaking at 1000 rpm. At the indicated time points, samples were fixed by addition of 0.5% paraformaldehyde (Carl Roth, Germany) in phosphate-buffered saline. The fixed samples were measured utilizing a BD FACSCalibur (BD Biosciences, Heidelberg, Germany). For quantification, a quadrant was set in the dot plot of respective channels on non-stimulated platelets. The appearance of double-colored events in the upper right quadrant (Q2) was quantified as percentage of total amount of labeled events (Q1+Q2+Q4) at every time point analyzed.
Western blotting
For determination of total (Akt) and phosphorylated (p-Akt) Akt protein abundance, whole cell protein extracts were obtained by direct lysis in Laemmli's Buffer and boiled at 100°C for 10 min. Proteins were separated on 12% SDS-polyacrylamide gels and transferred to PVDF membranes (Amersham Biosciences, Little Chalfont, UK). Nonspecific binding sites were blocked for 1 hour at room temperature with 5% nonfat dry milk in TBS-T. Individual membranes were incubated overnight at 4 °C with anti-AKT (#9272, Cell Signaling, Leiden, the Netherlands), anti-phospho-AKT (Thr308) (#13038, Cell Signaling) and anti-GAPDH (#2118, Cell Signaling). All primary antibodies were used at 1:1000. Membranes were then washed 3 times with TBS-T, followed by incubation with HRP-conjugated anti-rabbit secondary antibodies (#7074, 1:1000, Cell Signaling). Protein complexes were visualized with a chemiluminescent detection kit (WesternBright ECL Advansta, BioZym, Hessisch Oldendorf, Germany). Bands were quantified using ImageJ software (National Institute of Mental Health, USA).
Statistical analysis
Data are provided as means ± SEM; n represents the number of independent experiments. All data were tested for significance using ANOVA with Tukey's test as post-test or unpaired student's t-test as appropriate. Results with p<0.05 were considered statistically significant.
Results
The present study explored whether afatinib triggers activation and apoptosis of blood platelets. To this end, murine platelets were isolated from wild type mice and exposed to thrombin (0.005 U/ml or 0.01 U/ml) or CRP (2 µg/ml or 5 µg/ml) in the absence and presence of afatinib (18 µg/ml). In a first series of experiments, Orai1 abundance at the platelet surface was estimated utilizing specific antibodies. As illustrated in Fig. 1 , prior to treatment with thrombin or CRP, anti-Orai1 fluorescence was similar in the absence and presence of afatinib. Thrombin and CRP significantly enhanced anti-Orai1 fluorescence, an effect significantly blunted in the presence of afatinib.
Cytosolic Ca 2+ concentration ([Ca   2+ ] i ) was determined utilizing Fluo-3 fluorescence. As illustrated in Fig. 2, prior . Subsequent treatment with thrombin or CRP was followed by a profound significant increase of [Ca 2+ ] i in platelets, effects significantly blunted (thrombin) or virtually abolished (CRP) in the presence of afatinib.
Platelet degranulation was estimated from the increase of P-selectin abundance at the platelet surface, which was determined utilizing specific antibodies and flow cytometry. As illustrated in Fig. 3 , in resting platelets the P-selectin abundance was negligible at the surface and not significantly modified by afatinib treatment. Thrombin and CRP, both, markedly and significantly increased P-selectin abundance, an effect significantly blunted (thrombin) or virtually abolished (CRP) in the presence of afatinib. In a separate series, lower afatinib concentrations were employed (see Table 1 ). Only the effect of 5 µg/ml reached statistical significance (p<0.01).
Similarly, the abundance of active integrin α IIb β 3 was negligible at the surface of resting platelets (Fig. 4) and was not significantly modified by afatinib. Both, thrombin and CRP markedly and significantly increased the abundance of active integrin α IIb β 3 , effects again significantly blunted (thrombin) or even abolished (CRP) by afatinib. Again, the effect of lower afatinib concentrations was tested. In that series, the effects of 1 µg/ml (p<0.05) and of 5 µg/ml (p<0.01) reached statistical significance (Table 1) . Phosphatidylserine abundance was estimated from annexin-V-binding. As illustrated in Fig. 5 , the percentage of annexin-V positive platelets was again negligible in untreated platelets. In the absence of thrombin and CRP, afatinib increased annexin-V-binding slightly, but significantly. Thrombin and CRP markedly and significantly enhanced the percentage of annexin-V binding platelets, an effect again significantly blunted (thrombin) or even abolished (CRP) in the presence of afatinib. In a series using lower afatinib concentrations, the effect of 5 µg/ml (p<0.05) reached statistical significance (Table 1) .
Platelet volume was estimated from forward scatter, which was determined by flow cytometry. As illustrated in Fig. 6 , forward scatter of resting platelets was not significantly modified by afatinib treatment. Both, thrombin and CRP treatment was followed by marked and significant decreases of forward scatter, effects again significantly blunted or virtually abolished in the presence of afatinib. Table 1 . Effects of lower afatinib (AF) concentrations (µg/ml). Arithmetic means ± SEM (n = 4). *(p<0.05) and **(p<0.01) indicate statistically significant difference from absence of afatinib
Fig. 2. Afatinib sensitive thrombin-and CRP-induced increase of cytosolic Ca
2+ concentration. A-C. Original histogram overlays of Fluo-3 fluorescence reflecting cytosolic Ca 2+ activity in murine platelets (A) without and (B) with a 100 seconds thrombin (0.01 U/ml) treatment or (C) with a 150 seconds CRP (2 µg/ml) treatment without (grey areas) and with (black lines) presence of afatinib (18 µg/ml, 30 min). D. Arithmetic means ± SEM (n = 6) of Fluo-3 fluorescence reflecting cytosolic Ca 2+ activity in murine platelets without (left bars, resting) and with a 100 seconds thrombin (0.01 U/ml) treatment (middle bars) or a 150 seconds CRP (2 µg/ml) treatment (right bars) in the absence (white bars) and presence (black bars) of 18 µg/ml afatinib. *(p<0.05), ***(p<0.001) indicates statistically significant difference from absence of afatinib, ###(p<0.001) indicates statistically significant difference from absence of thrombin and CRP. A kit has been used for the detection of activated caspase 3. As illustrated in Fig. 7 , caspase activity was negligible in the absence of thrombin and CRP, irrespective of the presence of afatinib. Thrombin and CRP significantly enhanced caspase activity, an effect again significantly blunted in the presence of afatinib. In a series using lower afatinib concentrations, none of the afatinib effects reached statistical significance (Table 1) .
To elucidate the effect of thrombin and afatinib on platelet aggregation, platelets were labeled with two distinct dyes and the coincidence of the two dyes estimated by flow cytometry. As illustrated in Fig. 8, prior to thrombin or CRP treatment, aggregation of resting platelets was similarly low in the absence and presence of afatinib. Thrombin and CRP treatment significantly increased platelet aggregation, an effect significantly blunted by afatinib.
Western blotting was employed in order to test whether afatinib influences the phosphorylation of Akt. As illustrated in Fig. 9 , CRP treatment was followed by a marked and statistically significant increase of Akt phosphorylation, an effect significantly blunted in the presence of afatinib.
Discussion
The present observations reveal that high (18 µg/ml) concentrations of afatinib are followed by inhibition of the effect of thrombin and by virtual abolishment of the effect of collagen related peptide (CRP) on Orai1 abundance, [Ca 2+ ] i , P-selectin abundance, α IIb β 3 integrin activity, annexin-V-binding, caspase activity. Afatinib further significantly blunted thrombin and CRP induced platelet aggregation. The afatinib concentrations required for those effects are lower than the maximal plasma concentrations reported in patients of one study [42] . However, lower maximal concentrations have been reported in other studies [43] [44] [45] [46] [47] [48] [49] [50] and the vast majority of patients are probably not going to reach afatinib plasma levels of 1000 ng/ml and above and are therefore not prone to develop the effects analyzed in this paper. Nevertheless, those high concentrations could be reached following accidental overexposure to afatinib.
Afatinib had little or no effect on the measured parameters in the absence of thrombin or CRP. The inhibitory effect of afatinib on thrombin and CRP induced platelet activation and apoptosis is surprising, as the substance is well known to stimulate apoptosis of tumor cells [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Possibly, afatinib sensitive signaling molecules may serve different functions in tumor cells and blood platelets. On the other hand, the presently observed inhibition of platelet activation and apoptosis is probably not due to inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinases, which are inhibited at much lower concentrations [51, 52] . Notably, we confirm previous observations [14] that afatinib inhibits Akt, which plays a role in platelet activation [53] [54] [55] . This observation does, however, not rule out the involvement of further signaling molecules in the inhibitory effect of afatinib on platelet activation. and with subsequent 4 minutes treatment with thrombin (0.005 U/ml) (B,E) or CRP (2 µg/ml) (C,F). G,H. Arithmetic means ± SEM (n = 4) of platelet aggregation without (white circles) and with (black circles) prior afatinib (18 µg/ml) treatment as a function of time after addition of thrombin (0.005 U/ml) (G) or CRP (2 µg/ml) (H). *(p<0.05), **(p<0.01) indicates statistically significant difference from absence of afatinib. The inhibitory effect of afatinib on platelet activation and apoptosis may result from its inhibitory effect on thrombin and CRP induced increase of cytosolic Ca 2+ activity ([Ca   2+ ] i ) [32, 56] . Afatinib increased [Ca 2+ ] i in the absence of thrombin and CRP, but blunted the increase of [Ca 2+ ] i following exposure to thrombin or CRP. An increase of [Ca 2+ ] i is an important trigger of platelet activation and thus stimulator of arterial thrombosis [29] . Increased [Ca 2+ ] i further triggers cell membrane phospholipid scrambling with translocation of phosphatidylserine to the platelet surface [28, [57] [58] [59] . Phosphatidylserine translocation to the platelet surface supports the procoagulant function of platelets and is thus critically important for hemostasis [60] . On the other hand, phosphatidylserine exposing platelets are further bound to and engulfed by macrophages [61] . Whatever mechanisms involved, it is tempting to speculate that afatinib or related substances effective at lower concentrations may be used to counteract platelet activation and apoptosis. Further attempts to identify the primary target protein and subsequent search for related substances more specifically inhibiting that protein would be required.
In conclusion, afatinib blunts the thrombin-induced and virtually abrogates the CRPinduced [Ca 2+ ] i increase, degranulation, α IIb β 3 integrin activation, cell membrane scrambling, cell shrinkage, caspase activation and aggregation, and thus interferes with platelet activation, and apoptosis.
